目的：观察和研究药物±达拉奉在治疗脑干出血患者的临床效果以及安全性。方法整群选取该院2013年7月-2014年8月住院的65例急性脑干出血患者，随机分成观察组（30）和对照组（35例），给予对照组患者稳定血压与控制血糖，以及防治并发症等的处理，观察组患者在常规治疗的基础上，静脉滴注30 mg药物±达拉奉，2次/d，14 d为1个疗程。对比两组患者在治疗前后 ESS、ADL评分，将两组患者的治疗效果进行对比。结果在治疗以后14 d，观察组患者ESS与ADL评分分别为（13.4±13.1）分、（15.5±10.6）分，明显高于对照组，两组患者ESS 与ADL评分对比，具有显著的差异(P<0.01)，存在着统计学意义；观察组患者总有效率为96.67%，明显高于对照组患者（60.0%），两组患者治疗总有效率对比，亦存在显著的差异有统计学意义(P<0.001)。结论药物±达拉奉可以有效地治疗脑干出血症，改善预后，而且安全性可靠。%Objective To observe and study the clinical effect of edaravone on drug treatment in patients with brainstem hemor-rhage and security. Methods Select 65 cases of patients with acute brain stem in our hospital from 2013 July to 2014 August in hospital bleeding, were randomly divided into observation group (30) and control group (35 cases), the control of blood pressure and blood glucose control group given to patients with stable, treatment and prevention of complications, patients in the observation group based on routine treatment, intravenous note 30 mg drug edaravone, 2 times a day, 14 days are 1 treatment course. The two groups were compared before and after the treatment, ESS, ADL score, compared two groups of patients treatment effect. Results In the treatment group patients after 14 days, ESS and ADL score were observed for (13.4±13.1), (15.5±10.6), significantly higher than the control group, two groups of patients with ESS and ADL score comparison, with significant difference (P<0.01), there is statistical significance; the observation group patients total efficiency is 96.67%, significantly higher than the control group (60%patients), two patients in treatment group the total efficiency of contrast, but also has significant difference (P<0.001), with statisti-cal significance. Conclusion Drug edaravone can effectively treat brainstem hemorrhagic disease, improve the prognosis, and reli-able safety.
展开▼
